Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The goals of this study were to evaluate the efficacy and safety of sequentially blocking the
angiogenesis pathway via known antiangiogenic mechanisms, first with bevacizumab and then
addition of oral cyclophosphamide upon progression of cancer through bevacizumab. The drugs
used in this study were chosen because of their known antiangiogenic properties,
tolerability, and anti-ovarian cancer effects.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital